| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 16 | +62.50% | +0.51% | +0.18% | +0.33% | -1.58% | — |
| 14d | 16 | +68.75% | +0.31% | +0.16% | +0.15% | -3.60% | — |
| 30d | 16 | +62.50% | -0.57% | +1.37% | -1.94% | -4.70% | — |
| 60d | 16 | +62.50% | +0.85% | +2.63% | -1.77% | -7.88% | — |
| 90d | 16 | +56.25% | +4.96% | +0.96% | +3.99% | -9.21% | — |
| 180d | 16 | +87.50% | -31.29% | +5.20% | -36.49% | -35.65% | — |
| 1y | 16 | +75.00% | -20.48% | +18.32% | -38.80% | -72.41% | — |
| 2y | 16(3 pending) | +100.00% | -60.91% | +41.73% | -102.64% | -114.98% | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| XFOR X4 PHARMACEUTICALS, INC | PURCHASEGRANT Stock grant | 650,000 | — | — | 1,140,980 | Feb 12, 2025 | Feb 14, 2025 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | SALE Chief Operating Officer | 22,258 | $0.45 | $10.1K | 490,980 | Jan 24, 2025 | Jan 27, 2025 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | PURCHASEGRANT Stock grant | 61,178 | — | — | 513,238 | Jan 23, 2025 | Jan 27, 2025 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | SALE Chief Operating Officer | 67,695 | $0.57 | $38.3K | 452,060 | Oct 7, 2024 | Oct 8, 2024 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | PURCHASEGRANT Stock grant | 230,645 | — | — | 519,755 | Oct 4, 2024 | Oct 8, 2024 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | SALE Chief Operating Officer | 2,642 | $0.66 | $1.7K | 289,110 | Sep 9, 2024 | Sep 11, 2024 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | SALE Chief Operating Officer | 15,409 | $0.88 | $13.6K | 291,752 | Mar 11, 2024 | Mar 11, 2024 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | PURCHASEGRANT Stock grant | 428,248 | — | — | 428,248 | Feb 13, 2024 | Feb 16, 2024 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | SALE Chief Operating Officer | 3,683 | $1.01 | $3.7K | 307,161 | Feb 12, 2024 | Feb 12, 2024 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | SALE10b5-1 10b5-1 plan | 67,695 | $0.73 | $49.4K | 310,844 | Nov 1, 2023 | Nov 3, 2023 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | PURCHASEGRANT Stock grant | 230,645 | — | — | 378,539 | Oct 31, 2023 | Nov 2, 2023 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | SALE Chief Operating Officer | 2,642 | $1.25 | $3.3K | 147,894 | Sep 8, 2023 | Sep 12, 2023 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | SALE Chief Operating Officer | 464 | $1.89 | $877 | 150,536 | Jun 30, 2023 | Jul 5, 2023 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | SALE Chief Operating Officer | 857 | $1.93 | $1.7K | 151,000 | Jun 23, 2023 | Jun 26, 2023 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | SALE Chief Operating Officer | 857 | $2.23 | $1.9K | 151,857 | Jun 15, 2023 | Jun 16, 2023 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | SALE Chief Operating Officer | 18,192 | $0.84 | $15.3K | 152,714 | Mar 10, 2023 | Mar 13, 2023 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | SALE Chief Operating Officer | 4,348 | $0.93 | $4.0K | 170,906 | Feb 13, 2023 | Feb 15, 2023 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | PURCHASEGRANT Stock grant | 1,350,000 | — | — | 1,350,000 | Nov 7, 2022 | Nov 9, 2022 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | SALE Chief Operating Officer | 1,713 | — | — | 177,896 | Aug 17, 2022 | Aug 19, 2022 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | SALE Chief Operating Officer | 1,578 | — | — | 179,609 | Jun 30, 2022 | Jul 1, 2022 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | SALE Chief Operating Officer | 856 | — | — | 181,187 | Jun 24, 2022 | Jun 27, 2022 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | SALE Chief Operating Officer | 856 | — | — | 182,043 | Jun 16, 2022 | Jun 17, 2022 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | PURCHASEGRANT Stock grant | 105,000 | — | — | 182,899 | Mar 1, 2022 | Mar 1, 2022 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | SALE Chief Operating Officer | 12,545 | — | — | 77,899 | Feb 11, 2022 | Feb 14, 2022 ↗ | View → |
| XFOR X4 PHARMACEUTICALS, INC | PURCHASEGRANT Stock grant | 27,000 | — | — | 90,444 | Sep 8, 2021 | Sep 10, 2021 ↗ | View → |